Ultrasound-guided Acupotomy Treatment for Elbow Tendinopathy

Feasibility, Effectiveness, and Safety of Ultrasound-guided Acupotomy Treatment for Elbow Tendinopathy: a pilot randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009942

Enrollment

Registered

2024-11-22

Start date

2024-11-20

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device, Procedure/Surgery : 1. Intervention Phase: Total 3 Weeks - Experimental Group: Ultrasound-guided acupotomy therapy administered once per week for 3 weeks (total of 3 sessions). - Contr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adults aged 19 years or older 2) Individuals with pain at the lateral epicondyle of the elbow with a VAS score of = 30 mm 3) Individuals with elbow symptoms persisting for 6 weeks or more 4) Individuals who experience pain in at least two of the following four tests: a. Resisted wrist extension test b. Passive stretch of the wrist extensor test c. Resisted middle finger extension test d. Pain with grip strength test using a dynamometer 5) Individuals who voluntarily decided to participate after receiving an explanation of the study's purpose and procedures and provided written informed consent

Exclusion criteria

Exclusion criteria: 1) Individuals with upper limb pain due to cervical radiculopathy (e.g., cervical disc herniation, cervical stenosis) 2) Individuals with neurological disorders (e.g., nerve entrapment syndrome, polyneuropathy) 3) Individuals who undergone elbow surgery or recently experienced an acute elbow injury 4) Individuals with systemic inflammatory diseases (e.g., systemic arthritis) or chronic conditions (e.g., diabetic neuropathy, stroke, myocardial infarction, dementia, epilepsy) that may affect study outcomes 5) Individuals taking anticoagulants or antiplatelet agents, or those with bleeding disorders that may impair hemostasis 6) Individuals with acupuncture hypersensitivity, metal allergy, severe atopy, keloid skin, or other skin sensitivities 7) Individuals who received steroid injections for elbow tendinopathy within the last 6 months 8) Pregnant or breastfeeding individuals, or those planning a pregnancy 9) Individuals unable to complete patient-reported outcome measures independently or with assistance from a caregiver/researcher 10) Individuals deemed unsuitable for clinical trial participation by the clinical researcher

Design outcomes

Primary

Measure	Time frame
Feasibility;Safety assessment (Adverse effect)	—

Secondary

Measure	Time frame
Elbow pain intensity (Visual analog scale 0-100mm) ;Patient-Rated Tennis Elbow Evaluation (PRTEE);Painless and Maximum Grip Strengths ;Euroqol-5 Dimensions-5 Levels / Visual analog scale;Patient Global Impression of change (PGIC)	—

Countries

Korea, Republic of

Contacts

Public ContactEunseok Kim

Pusan National University Korean Medicine Hospital

mybestcando@naver.com+82-55-360-5950

Outcome results